Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial - PubMed
3 hours ago
- #Diabetes
- #Cardiovascular Prevention
- #Evolocumab
- VESALIUS-CV trial investigated evolocumab's effect on preventing first major cardiovascular events in high-risk patients with diabetes but without known significant atherosclerosis.
- The study included 3,655 patients, randomized to receive evolocumab or placebo on top of optimally tolerated statin therapy, with a median follow-up of 4.8 years.
- Evolocumab significantly lowered LDL-C levels to a median of 52 mg/dL compared to 111 mg/dL in the placebo group at 48 weeks.
- Evolocumab reduced the risk of 3-P MACE (coronary heart disease death, myocardial infarction, or ischemic stroke) with a hazard ratio of 0.69 and a between-group difference of 2.1%.
- It also reduced 4-P MACE (3-P MACE plus ischemia-driven arterial revascularization) with a hazard ratio of 0.69 and a between-group difference of 2.9%.
- All-cause mortality was lower in the evolocumab group with a hazard ratio of 0.76 compared to placebo.